WO2003000295A3 - Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors - Google Patents

Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors Download PDF

Info

Publication number
WO2003000295A3
WO2003000295A3 PCT/IB2002/001571 IB0201571W WO03000295A3 WO 2003000295 A3 WO2003000295 A3 WO 2003000295A3 IB 0201571 W IB0201571 W IB 0201571W WO 03000295 A3 WO03000295 A3 WO 03000295A3
Authority
WO
WIPO (PCT)
Prior art keywords
self
transfer protein
cholesteryl ester
protein inhibitors
ester transfer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2002/001571
Other languages
French (fr)
Other versions
WO2003000295A2 (en
Inventor
Michael Jon Gumkowski
Sharad Balasaheb Murdande
Michael Ellis Perlman
Franco LOMBARDO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to SK1517-2003A priority Critical patent/SK15172003A3/en
Priority to JP2003506937A priority patent/JP2005500314A/en
Priority to EA200301139A priority patent/EA200301139A1/en
Priority to EEP200400024A priority patent/EE200400024A/en
Priority to CA002455288A priority patent/CA2455288A1/en
Priority to MXPA04000014A priority patent/MXPA04000014A/en
Priority to EP02732994A priority patent/EP1453544A2/en
Priority to IL15876502A priority patent/IL158765A0/en
Priority to BR0210505-5A priority patent/BR0210505A/en
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Priority to HU0400263A priority patent/HUP0400263A2/en
Priority to KR10-2003-7016651A priority patent/KR20040015746A/en
Publication of WO2003000295A2 publication Critical patent/WO2003000295A2/en
Priority to IS7014A priority patent/IS7014A/en
Priority to NO20035632A priority patent/NO20035632L/en
Anticipated expiration legal-status Critical
Publication of WO2003000295A3 publication Critical patent/WO2003000295A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Colloid Chemistry (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)

Abstract

CETP Inhibitors have improved solubility and bioavailability in a lipophilic vehicle comprising a digestible oil, a lipophilic solvent, or a surfactant. Preferred such compositions are self-emulsifying or self-microemulsifying, and comprise 1. a CETP inhibitor; 2. a cosolvent; 3. a surfactant having an HLB of 1 to 8; 4. a surfactant having an HLB of over 8 to 20; and 5. optionally, a digestible oil.
PCT/IB2002/001571 2001-06-21 2002-05-03 Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors Ceased WO2003000295A2 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
BR0210505-5A BR0210505A (en) 2001-06-21 2002-05-03 Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors
EA200301139A EA200301139A1 (en) 2001-06-21 2002-05-03 SELF-EMULATING PREPARATIONS OF THE INHIBITORS OF CHOLESTEROL ETHERUM PROTECTIVE
EEP200400024A EE200400024A (en) 2001-06-21 2002-05-03 Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors
CA002455288A CA2455288A1 (en) 2001-06-21 2002-05-03 Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors
MXPA04000014A MXPA04000014A (en) 2001-06-21 2002-05-03 Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors.
EP02732994A EP1453544A2 (en) 2001-06-21 2002-05-03 Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors
IL15876502A IL158765A0 (en) 2001-06-21 2002-05-03 Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors
SK1517-2003A SK15172003A3 (en) 2001-06-21 2002-05-03 Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors
HU0400263A HUP0400263A2 (en) 2001-06-21 2002-05-03 Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors
JP2003506937A JP2005500314A (en) 2001-06-21 2002-05-03 Self-emulsifying formulation of cholesterol ester transfer protein inhibitor
KR10-2003-7016651A KR20040015746A (en) 2001-06-21 2002-05-03 Self-Emulsifying Formulations of Cholesteryl Ester Transfer Protein Inhibitors
IS7014A IS7014A (en) 2001-06-21 2003-10-31 Self-adhesive formulations of cholesterol ester transporters
NO20035632A NO20035632L (en) 2001-06-21 2003-12-17 Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30002801P 2001-06-21 2001-06-21
US60/300,028 2001-06-21

Publications (2)

Publication Number Publication Date
WO2003000295A2 WO2003000295A2 (en) 2003-01-03
WO2003000295A3 true WO2003000295A3 (en) 2004-05-27

Family

ID=23157363

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2002/001571 Ceased WO2003000295A2 (en) 2001-06-21 2002-05-03 Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors

Country Status (33)

Country Link
US (2) US6962931B2 (en)
EP (1) EP1453544A2 (en)
JP (1) JP2005500314A (en)
KR (1) KR20040015746A (en)
CN (1) CN1635911A (en)
AP (1) AP2002002559A0 (en)
AR (1) AR034599A1 (en)
BG (1) BG108486A (en)
BR (1) BR0210505A (en)
CA (1) CA2455288A1 (en)
CR (1) CR7163A (en)
CZ (1) CZ20033341A3 (en)
EA (1) EA200301139A1 (en)
EC (1) ECSP034875A (en)
EE (1) EE200400024A (en)
GT (1) GT200200124A (en)
HN (1) HN2002000153A (en)
HU (1) HUP0400263A2 (en)
IL (1) IL158765A0 (en)
IS (1) IS7014A (en)
MA (1) MA27034A1 (en)
MX (1) MXPA04000014A (en)
NO (1) NO20035632L (en)
OA (1) OA12619A (en)
PA (1) PA8548601A1 (en)
PE (1) PE20030128A1 (en)
PL (1) PL368850A1 (en)
SK (1) SK15172003A3 (en)
SV (1) SV2003001103A (en)
TN (1) TNSN03139A1 (en)
UY (1) UY27344A1 (en)
WO (1) WO2003000295A2 (en)
ZA (1) ZA200308561B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7276536B2 (en) 2003-03-17 2007-10-02 Japan Tobacco Inc. Method for increasing the bioavailability of the active form of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino) phenyl] 2-methylpropanethioate
US10973801B2 (en) 2018-03-14 2021-04-13 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL143604A0 (en) * 1998-12-30 2002-04-21 Dexcel Ltd Dispersable concentrate for the delivery of cyclosporin
US7732404B2 (en) * 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
JP4031232B2 (en) * 2001-11-09 2008-01-09 カプスゲル・ジャパン株式会社 New capsule
DE60320940D1 (en) * 2002-02-01 2008-06-26 Pfizer Prod Inc PHARMACEUTICAL COMPOSITIONS OF AMORPHOUS DISPERSIONS OF ACTIVE SUBSTANCES AND LIPOPHILIC MICROPHASE-BASED MATERIALS
AU2003219942A1 (en) * 2002-03-01 2003-09-16 Cesi Chemical, A Flotek Company Composition and process for well cleaning
US20040175341A1 (en) * 2003-03-04 2004-09-09 Manning Monna Marie Microemulsion for cosmetic or pharmaceutical use containing an active ingredient
KR20080008440A (en) * 2003-03-17 2008-01-23 니뽄 다바코 산교 가부시키가이샤 Pharmaceutical Compositions of CEPT Inhibitors
ZA200508160B (en) * 2003-03-17 2007-01-31 Japan Tobacco Inc Method for increasing the oral bioavailability of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl) 2-methyl-propanethioate
TWI393560B (en) * 2003-05-02 2013-04-21 Japan Tobacco Inc Combination comprising s-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]2-methylpropanethioate and an hmg coa reductase inhibitor
JP2007501218A (en) * 2003-08-04 2007-01-25 ファイザー・プロダクツ・インク Pharmaceutical composition of adsorbate of amorphous drug and lipophilic microphase-forming substance
WO2005033082A2 (en) * 2003-09-30 2005-04-14 Pfizer Products Inc. Cetp inhibitors and metabolites thereof
WO2005037796A1 (en) * 2003-10-08 2005-04-28 Eli Lilly And Company Compounds and methods for treating dyslipidemia
US20050220866A1 (en) * 2004-04-02 2005-10-06 Dr. Reddy's Laboratories Limited Novel capsule formulations of etoposide for oral use
US7700774B2 (en) 2004-12-20 2010-04-20 Dr. Reddy's Laboratories Ltd. Heterocyclic compounds and their pharmaceutical compositions
MX2007007919A (en) 2004-12-31 2008-01-22 Reddy Us Therapeutics Inc Novel benzylamine derivatives as cetp inhibitors.
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
US20090169583A1 (en) * 2005-02-08 2009-07-02 Pfizer, Inc. Solid Adsorbates of Hydrophobic Drugs
US7623458B2 (en) * 2005-09-30 2009-11-24 The Boeing Company System and method for providing integrated services across cryptographic boundaries in a network
ATE516016T1 (en) 2005-12-05 2011-07-15 Merck Sharp & Dohme SELF-EMULSIFYING FORMULATIONS OF CETP INHIBITORS
KR101164516B1 (en) * 2005-12-31 2012-07-13 태슬리 파마슈티컬 그룹 컴퍼니 리미티드 Pharmaceutical composition containing chenopodium ambrosioides extract and its preparing process and application
WO2008005352A2 (en) * 2006-06-30 2008-01-10 Schering Corporation Solid dose formulations of a thrombin receptor antagonist
EP1961412A1 (en) * 2006-12-27 2008-08-27 LEK Pharmaceuticals D.D. Self-microemulsifying drug delivery systems
US9222013B1 (en) 2008-11-13 2015-12-29 Cesi Chemical, Inc. Water-in-oil microemulsions for oilfield applications
WO2010066593A1 (en) * 2008-12-08 2010-06-17 F. Hoffmann-La Roche Ag Combined drug administration
US20100273730A1 (en) * 2009-04-27 2010-10-28 Innopharmax, Inc. Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof
SMT202000093T1 (en) 2009-06-16 2020-03-13 Pfizer Dosage forms of apixaban
CA2690490C (en) * 2010-01-19 2012-06-26 Accucaps Industries Limited Pharmaceutical formulations of loratadine for encapsulation and combinations thereof
EA201391742A1 (en) * 2011-05-20 2014-04-30 Авентис Фармасьютикалз Инк. PHARMACEUTICAL COMPOSITION INCLUDING FEXOPHENADINE
JP5964965B2 (en) 2011-08-18 2016-08-03 ドクター レディズ ラボラトリーズ リミテッド Substituted heterocyclic amine compounds as cholesteryl ester transfer protein (CETP) inhibitors
IN2014CN02290A (en) 2011-09-27 2015-06-19 Reddys Lab Ltd Dr
EP2768486B1 (en) * 2011-10-21 2018-10-03 First Tech International Limited Tocotrienol compositions
EP2838970B1 (en) 2012-04-15 2016-12-28 Flotek Chemistry, LLC Surfactant formulations for foam flooding
US11407930B2 (en) 2012-05-08 2022-08-09 Flotek Chemistry, Llc Compositions and methods for enhancement of production of liquid and gaseous hydrocarbons
US9200192B2 (en) 2012-05-08 2015-12-01 Cesi Chemical, Inc. Compositions and methods for enhancement of production of liquid and gaseous hydrocarbons
US20160000799A1 (en) * 2013-02-21 2016-01-07 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of cetp inhibitors
US10941106B2 (en) 2013-03-14 2021-03-09 Flotek Chemistry, Llc Methods and compositions incorporating alkyl polyglycoside surfactant for use in oil and/or gas wells
US11254856B2 (en) 2013-03-14 2022-02-22 Flotek Chemistry, Llc Methods and compositions for use in oil and/or gas wells
US9868893B2 (en) 2013-03-14 2018-01-16 Flotek Chemistry, Llc Methods and compositions for use in oil and/or gas wells
US9884988B2 (en) 2013-03-14 2018-02-06 Flotek Chemistry, Llc Methods and compositions for use in oil and/or gas wells
US11180690B2 (en) 2013-03-14 2021-11-23 Flotek Chemistry, Llc Diluted microemulsions with low surface tensions
US10421707B2 (en) 2013-03-14 2019-09-24 Flotek Chemistry, Llc Methods and compositions incorporating alkyl polyglycoside surfactant for use in oil and/or gas wells
US9464223B2 (en) 2013-03-14 2016-10-11 Flotek Chemistry, Llc Methods and compositions for use in oil and/or gas wells
US9428683B2 (en) 2013-03-14 2016-08-30 Flotek Chemistry, Llc Methods and compositions for stimulating the production of hydrocarbons from subterranean formations
US10053619B2 (en) 2013-03-14 2018-08-21 Flotek Chemistry, Llc Siloxane surfactant additives for oil and gas applications
US9068108B2 (en) 2013-03-14 2015-06-30 Cesi Chemical, Inc. Methods and compositions for stimulating the production of hydrocarbons from subterranean formations
US10577531B2 (en) 2013-03-14 2020-03-03 Flotek Chemistry, Llc Polymers and emulsions for use in oil and/or gas wells
US9321955B2 (en) 2013-06-14 2016-04-26 Flotek Chemistry, Llc Methods and compositions for stimulating the production of hydrocarbons from subterranean formations
US10717919B2 (en) 2013-03-14 2020-07-21 Flotek Chemistry, Llc Methods and compositions for use in oil and/or gas wells
US10590332B2 (en) 2013-03-14 2020-03-17 Flotek Chemistry, Llc Siloxane surfactant additives for oil and gas applications
US10287483B2 (en) 2013-03-14 2019-05-14 Flotek Chemistry, Llc Methods and compositions for use in oil and/or gas wells comprising a terpene alcohol
US10000693B2 (en) 2013-03-14 2018-06-19 Flotek Chemistry, Llc Methods and compositions for use in oil and/or gas wells
CN104706586A (en) * 2013-12-16 2015-06-17 天津迈迪瑞康生物医药科技有限公司 Cleviprex fat emulsion concentrated solution, preparation method and application thereof
CN104706689A (en) * 2013-12-16 2015-06-17 天津迈迪瑞康生物医药科技有限公司 Oleum fructus bruceae fat emulsion concentrated solution, preparation method and application thereof
CN104706587A (en) * 2013-12-16 2015-06-17 天津迈迪瑞康生物医药科技有限公司 Etomidate fat emulsion concentrated solution, preparation method and application thereof
US9890624B2 (en) 2014-02-28 2018-02-13 Eclipse Ior Services, Llc Systems and methods for the treatment of oil and/or gas wells with a polymeric material
US9890625B2 (en) 2014-02-28 2018-02-13 Eclipse Ior Services, Llc Systems and methods for the treatment of oil and/or gas wells with an obstruction material
CA2891278C (en) 2014-05-14 2018-11-06 Cesi Chemical, Inc. Methods and compositions for use in oil and / or gas wells
US10294757B2 (en) 2014-07-28 2019-05-21 Flotek Chemistry, Llc Methods and compositions related to gelled layers in oil and/or gas wells
EP3215128B1 (en) * 2014-11-04 2019-09-04 Innopharmax, Inc. Oral administration of unstable or poorly-absorbed drugs
CN104546710A (en) * 2014-12-20 2015-04-29 长沙佰顺生物科技有限公司 Anacetrapib nanoemulsion and preparation method thereof
CN104490775A (en) * 2014-12-20 2015-04-08 长沙佰顺生物科技有限公司 Anacetrapib fat emulsion and preparation method thereof
KR101590072B1 (en) * 2014-12-23 2016-01-29 한미약품 주식회사 Composition for self-emulsifying drug delivery system comprising dutasteride
JP6605047B2 (en) 2015-05-28 2019-11-13 ドクター・レディーズ・ラボラトリーズ・リミテッド Celecoxib oral composition for the treatment of pain
WO2017181141A2 (en) 2016-04-15 2017-10-19 Novira Therapeutics, Inc. Combinations and methods comprising a capsid assembly inhibitor
US10934472B2 (en) 2017-08-18 2021-03-02 Flotek Chemistry, Llc Compositions comprising non-halogenated solvents for use in oil and/or gas wells and related methods
US11053433B2 (en) 2017-12-01 2021-07-06 Flotek Chemistry, Llc Methods and compositions for stimulating the production of hydrocarbons from subterranean formations
EA202092131A1 (en) 2018-03-14 2020-11-27 Кэнди Терапьютикс Лимитед NEW PHARMACEUTICAL PREPARATION CONTAINING DUAL ANTAGONISTS OF THE NK-1 / NK-3 RECEPTOR
AU2019386859A1 (en) * 2018-11-26 2021-05-27 Hepion Pharmaceuticals, Inc. Pharmaceutical formulations of cyclosporine analogs
SG11202111251SA (en) 2019-04-11 2021-11-29 R P Scherer Technologies Llc Formulation for oral delivery of proteins, peptides and small molecules with poor permeability
CN110252395B (en) * 2019-07-01 2020-10-16 湖北远大生命科学与技术有限责任公司 Catalyst for preparing high-purity taurine and application thereof
US11104843B2 (en) 2019-10-10 2021-08-31 Flotek Chemistry, Llc Well treatment compositions and methods comprising certain microemulsions and certain clay control additives exhibiting synergistic effect of enhancing clay swelling protection and persistency
FR3110852B1 (en) 2020-05-27 2024-03-15 Centre Nat Rech Scient EMULSIONS FOR CONTROLLED DRUG RELEASE
US11512243B2 (en) 2020-10-23 2022-11-29 Flotek Chemistry, Llc Microemulsions comprising an alkyl propoxylated sulfate surfactant, and related methods
CN114681470A (en) 2020-12-28 2022-07-01 雷迪博士实验室有限公司 Method of treating pain
CN119259277B (en) * 2024-11-26 2026-04-03 昆明理工大学 Application of a nitrogen heterocyclic thion compound
US12533358B1 (en) 2025-05-14 2026-01-27 Bayer Consumer Care Ag Methods of treatment with elinzanetant

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19741399A1 (en) * 1997-09-19 1999-03-25 Bayer Ag New tetrahydroquinoline derivatives useful in treatment of elevated lipid levels and arteriosclerosis
WO1999014204A1 (en) * 1997-09-16 1999-03-25 G.D. Searle & Co. Substituted 1,2,4-triazoles useful for inhibiting cholesteryl ester transfer protein activity
WO1999041237A1 (en) * 1998-02-13 1999-08-19 G.D. Searle & Co. Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity
US5993858A (en) * 1996-06-14 1999-11-30 Port Systems L.L.C. Method and formulation for increasing the bioavailability of poorly water-soluble drugs
WO2000017165A1 (en) * 1998-09-17 2000-03-30 Pfizer Products Inc. 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors
WO2000017164A1 (en) * 1998-09-17 2000-03-30 Pfizer Products Inc. 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors
WO2000018723A1 (en) * 1998-09-25 2000-04-06 Monsanto Company Substituted n-aliphatic-n-aromatic tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
EP0992496A1 (en) * 1998-09-17 2000-04-12 Pfizer Products Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines as CETP inhibitors
EP1020439A1 (en) * 1997-02-12 2000-07-19 Japan Tobacco Inc. Cetp activity inhibitors
WO2001040190A1 (en) * 1999-11-30 2001-06-07 Pfizer Products Inc. 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as cetp inhibitor

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI65914C (en) 1978-03-07 1984-08-10 Sandoz Ag FRAMEWORK FOR PHARMACEUTICAL COMPOSITION OF CYCLOSPORINE A
GB9208712D0 (en) 1992-04-22 1992-06-10 Sandoz Ltd Pharmaceutical compositions containing cyclosporin derivates
AU2517095A (en) 1994-05-19 1995-12-18 R.P. Scherer International Corporation Solutions of aryl or heteroaryl substituted alkanoic acids in lipophilic solvents and soft gelatin capsules containing such solutions
JPH11504028A (en) 1995-04-24 1999-04-06 イースム リサーチ ディベロップメント カンパニー オブ ザ ヒーブル ユニバーシティ オブ エルサレム Self-emulsifying compounds that create oil / water emulsions
GB9608719D0 (en) 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
US5958876A (en) 1996-06-19 1999-09-28 Novartis Ag Cyclosporin-containing pharmaceutical compositions
DK0869810T3 (en) 1996-06-19 2005-02-07 Novartis Ag Cyclosporin-containing soft capsule preparations
US6063762A (en) 1997-12-05 2000-05-16 Chong Kun Dang Corp. Cyclosporin-containing microemulsion preconcentrate composition
US6140342A (en) * 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
US6147090A (en) 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
IL143604A0 (en) 1998-12-30 2002-04-21 Dexcel Ltd Dispersable concentrate for the delivery of cyclosporin
US6482862B1 (en) * 1999-12-20 2002-11-19 G.D. Searle & Co. Method of using substituted N-benzyl-N-phenyl aminoalcohols for inhibiting cholesteryl ester transfer protein activity
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
EP1401503B1 (en) * 2001-06-22 2007-05-09 Pfizer Products Inc. Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug and a solubility-enhancing polymer
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
MXPA03011784A (en) * 2001-06-22 2004-04-02 Pfizer Prod Inc Pharmaceutical compositions of dispersions of drugs and neutral polymers.
WO2003000226A2 (en) * 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
CN1688291A (en) * 2002-02-01 2005-10-26 辉瑞产品公司 Immediate release dosage forms containing solid drug dispersions
DE60320940D1 (en) * 2002-02-01 2008-06-26 Pfizer Prod Inc PHARMACEUTICAL COMPOSITIONS OF AMORPHOUS DISPERSIONS OF ACTIVE SUBSTANCES AND LIPOPHILIC MICROPHASE-BASED MATERIALS
ES2300628T3 (en) * 2002-12-20 2008-06-16 Pfizer Products Inc. DOSAGE FORMS THAT INCLUDE A CETP INHIBITOR AND A HMG-COA REDUCTASA INHIBITOR.
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993858A (en) * 1996-06-14 1999-11-30 Port Systems L.L.C. Method and formulation for increasing the bioavailability of poorly water-soluble drugs
EP1020439A1 (en) * 1997-02-12 2000-07-19 Japan Tobacco Inc. Cetp activity inhibitors
WO1999014204A1 (en) * 1997-09-16 1999-03-25 G.D. Searle & Co. Substituted 1,2,4-triazoles useful for inhibiting cholesteryl ester transfer protein activity
DE19741399A1 (en) * 1997-09-19 1999-03-25 Bayer Ag New tetrahydroquinoline derivatives useful in treatment of elevated lipid levels and arteriosclerosis
WO1999041237A1 (en) * 1998-02-13 1999-08-19 G.D. Searle & Co. Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity
WO2000017165A1 (en) * 1998-09-17 2000-03-30 Pfizer Products Inc. 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors
WO2000017164A1 (en) * 1998-09-17 2000-03-30 Pfizer Products Inc. 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors
EP0992496A1 (en) * 1998-09-17 2000-04-12 Pfizer Products Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines as CETP inhibitors
WO2000018723A1 (en) * 1998-09-25 2000-04-06 Monsanto Company Substituted n-aliphatic-n-aromatic tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
WO2001040190A1 (en) * 1999-11-30 2001-06-07 Pfizer Products Inc. 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as cetp inhibitor

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7276536B2 (en) 2003-03-17 2007-10-02 Japan Tobacco Inc. Method for increasing the bioavailability of the active form of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino) phenyl] 2-methylpropanethioate
US10973801B2 (en) 2018-03-14 2021-04-13 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen

Also Published As

Publication number Publication date
AP2002002559A0 (en) 2002-06-30
BR0210505A (en) 2004-05-18
US20060014788A1 (en) 2006-01-19
IS7014A (en) 2003-10-31
HUP0400263A2 (en) 2005-03-29
WO2003000295A2 (en) 2003-01-03
IL158765A0 (en) 2004-05-12
US20030022944A1 (en) 2003-01-30
OA12619A (en) 2006-06-12
SV2003001103A (en) 2003-03-18
UY27344A1 (en) 2003-01-31
EE200400024A (en) 2004-06-15
SK15172003A3 (en) 2004-11-03
GT200200124A (en) 2003-09-22
US6962931B2 (en) 2005-11-08
CR7163A (en) 2004-02-23
TNSN03139A1 (en) 2005-12-23
NO20035632D0 (en) 2003-12-17
NO20035632L (en) 2004-02-18
PA8548601A1 (en) 2003-09-05
KR20040015746A (en) 2004-02-19
ZA200308561B (en) 2004-11-17
EA200301139A1 (en) 2004-12-30
CA2455288A1 (en) 2003-01-03
MA27034A1 (en) 2004-12-20
ECSP034875A (en) 2004-01-28
EP1453544A2 (en) 2004-09-08
PL368850A1 (en) 2005-04-04
AR034599A1 (en) 2004-03-03
CZ20033341A3 (en) 2004-10-13
CN1635911A (en) 2005-07-06
MXPA04000014A (en) 2004-05-21
HN2002000153A (en) 2002-11-05
JP2005500314A (en) 2005-01-06
PE20030128A1 (en) 2003-02-28
BG108486A (en) 2005-03-31

Similar Documents

Publication Publication Date Title
MXPA04000014A (en) Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors.
PL365168A1 (en) Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
CA2383916A1 (en) Dispersion formulations containing lipase inhibitors
WO2006057903A3 (en) Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide
CA2344350A1 (en) 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
AU2001251376A1 (en) Stability enhanced water-in-oil emulsion and method for using same
CA2340056A1 (en) Pharmaceutical compositions containing lipase inhibitors
AU3924895A (en) Pharmaceutical compositions
WO2001062226A3 (en) Homogenous solid matrix containing vegetable proteins
CY1109135T1 (en) PHARMACEUTICAL SOLUTION WHICH INCLUDES RITONAVIR, A SOLVENT (LONG CHAIN OIL FAT) AND WATER
AU2002234546A1 (en) Food composition suitable for shallow frying comprising sunflower lecithin
CA2135192A1 (en) Vaccinal fluid water-in-oil emulsions containing a metabolizable oil
WO2000072867A3 (en) Substantially oil-free cyclosporin compositions
WO2004082593A3 (en) Pharmaceutical compositions of cetp inhibitors
ATE404172T1 (en) DISPERSIBLE CONCENTRATE FOR ADMINISTRATION OF CYCLOSPORINE
AU3591301A (en) Ester derivatives of dimethylpropionic acid and pharmacetuical compositions containing them
AU2001283255A1 (en) Products comprising corn oil and corn meal obtained from high oil corn
WO2002036110A3 (en) Oral self-emulsifying formulations of pyranone protease inhibitors
HUP9901887A2 (en) Compositions comprising an hiv protease inhibitor and a water soluble vitamin e compound
AU2001252741A1 (en) Pharmaceutical composition containing itraconazole with gastric ph-independentlyimproved solubility and preparation method thereof
SI1917958T1 (en) Improved HIV protease inhibitors pharmaceutical formulations
DOP2002000419A (en) SELF-EMULSIONING FORMULATIONS OF INHIBITORS OF THE ESTER CHOLESTERILE TRANSFER PROTECTION.
WO2001022969A3 (en) Vasopressin agonist formulation and process
WO2002053120A3 (en) Cosmetic and dermatological light protection formulations containing benzotriazole derivatives and surfactant sucrose esters
AU2001277016A1 (en) Method for removing contaminants from vegetable oil and lecithin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003/08561

Country of ref document: ZA

Ref document number: 200308561

Country of ref document: ZA

Ref document number: 529268

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 158765

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 1043/MUMNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2002732994

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200301139

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2002304366

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: CR2003-007163

Country of ref document: CR

WWW Wipo information: withdrawn in national office

Ref document number: CR2003-007163

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: PV2003-3341

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 15172003

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: P20031044A

Country of ref document: HR

Ref document number: 2455288

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1-2003-501333

Country of ref document: PH

Ref document number: 1200301141

Country of ref document: VN

Ref document number: P-1002/03

Country of ref document: YU

WWE Wipo information: entry into national phase

Ref document number: 2003506937

Country of ref document: JP

Ref document number: 1020037016651

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 10848602

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 028124820

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/000014

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: CR2003-007163

Country of ref document: CR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002732994

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2003-3341

Country of ref document: CZ